Thermo Fisher Eyes 15-20% India Growth Over Five Years

Thermo Fisher Scientific is targeting a 15-20% increase in its India customer base over the next five years, betting on the country’s rapidly expanding biopharma research and manufacturing ecosystem. Reported by Reuters on 10 August 2026, the strategy was outlined by Srinath Venkatesh, managing director for India and South Asia, and underscores India’s growing importance as a strategic market for global analytical instrumentation and life sciences suppliers.

Thermo Fisher expects continued double-digit growth in India, driven by rising demand from biopharma, semiconductor and clean energy sectors. India has historically been recognised as the “pharmacy of the world” for its generic drug production, but the market is undergoing a structural shift toward biologics, biosimilars and more complex biopharmaceuticals requiring significantly more sophisticated analytical infrastructure. Venkatesh positioned laboratory quality standards adoption as a key driver, noting that as more Indian laboratories align with international standards, demand for Thermo Fisher’s analytical instrumentation, antibodies and genetic analysis products expands correspondingly.

The strategy builds on Thermo Fisher’s late-2025 launch of a new Bioprocess Design Center in Hyderabad, part of an Asian tri-hub network alongside expanded facilities in Incheon and Singapore. Thermo Fisher currently employs more than 5,000 people in India. The India expansion also positions Thermo Fisher to capitalise on emerging local demand for obesity drugs and biosimilars as Indian drugmakers accelerate entry. The strategy intensifies competitive pressure across analytical instrumentation suppliers, with Agilent Technologies, Waters Corporation, Shimadzu and Bruker all pursuing India growth strategies against local CDMOs including Biocon, Syngene, Aragen Life Sciences and Piramal Pharma Solutions.

The commercial signal is India solidifying its position as a top-tier global biopharmaceutical growth market as domestic drugmakers transition from generics to biologics. Thermo Fisher’s India strategy provides a proxy for the wider category opportunity. Expect Agilent, Waters, Shimadzu, Bruker and Siemens Healthineers to sharpen their India commercial positioning through 2027 as Indian labs continue adopting international quality standards.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!